Lunch (Clinical Urology Moderated Poster Session)

Location: Plaza Ballroom
Chair: Prof Henry Woo

Back to list


Supported by

Preliminary Results of a Phase 2 Multicentre Study of Linac-based Stereotactic Radiotherapy Boost for Intermediate and High Risk Prostate Cancer (PROMETHEUS) – David Pryor

Assessing the safety and learning curve of hydrogel spacer device placement in a regional centre – Alexander Nesbitt

Five years of focal irreversible electroporation for prostate cancer – What have we learned? – Alexandar Blazevski

Survivorship from Robotic Assisted Laparoscopic Prostatectomy (RALP) considering Lower Urinary Tract Symptoms (LUTS) – Andrew Strahan

Pathological characteristics of prostate cancer in younger men – James Macneil

Distribution of prostate cancer treatment options in newly diagnosed patients – Yeji Ham

Gleason score and calendar month influence likelihood of discussion at Multidisciplinary meeting – Yeji Ham

Primary Androgen Deprivation Therapy as Monotherapy in Unfavourable Intermediate and High Risk Localised Prostate Cancer – A Singaporean Single-centre Perspective – Han Jie Lee

Androgen Receptor (AR) Anomalies and Efficacy of Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From the Phase 3 SPARTAN Study – Paul N. Mainwaring

PSA Age-Specific Reference Ranges for Puerto Rican Prostate Cancer Patients – Ernesto Esteban

PIRADS 3 lesions: Should we bother with MRI-Ultrasound fusion biopsy – Sean Heywood

MRI-TRUS fusion biopsy has a high rate of down grading of grade group 3 and 4 lesions – Sean Heywood

Biopsy outcomes for PIRADS 3 patients in Melbourne – Daniel Costello

Oncologic outcomes of Gleason 3+4 Prostate Cancer: A retrospective analysis of experience in Victoria – Homayoun (Homi) Zargar

Implementation of an electronic Patient Reported Outcome system in the Prostate Clinic at the Vancouver Prostate Centre – Tia (Celestia) Higano